Filing Flows › Johnson & Johnson (JNJ) › Guidance & outlook
Johnson & Johnson (JNJ) guidance and outlook
Johnson & Johnson (JNJ) raised some and lowered other parts of its guidance on Oct 13, 2026: Revenue $101.2B for FY2026; Revenue +7.4% for FY2026; EPS $10.95–$11.05 for FY2026. Johnson & Johnson's 10-Q filed Oct 21, 2026 makes 4 forward-looking statements, 2 of them new and 4 no longer said since the filing before.
Guidance and outlook
Latest guidance
| Metric | Period | Range | Change |
|---|---|---|---|
| Revenue | FY2026 | $101.2B | reaffirmed |
| Revenue | FY2026 | +7.4% | raised |
| EPS | FY2026 | $10.95–$11.05 | lowered |
From the earnings release filed Oct 13, 2026 (8-K on EDGAR).
Forward-looking statements, 10-Q filed Oct 21, 2026
- The Company expects STELARA biosimilars to continue to negatively impact the Company’s sales of STELARA.
- new · Subject to each covered entity’s submission of appropriate claims data, the Company will continue to offer the covered entity access to 340B pricing on the Company’s covered outpatient drugs up-front at the time of purchase.
- new · In October 2025, the Company announced its intention to separate its Orthopaedics business and expects the separation to be completed in mid-2027.
- The Company expects to continue the practice of paying regular quarterly cash dividends.
Johnson & Johnson's latest quarter
Johnson & Johnson, Q3 2026: revenue $25.4B (+6% year over year), operating margin 0.1%, net earnings $210M, operating cash flow $7.7B. The chart follows the revenue to costs, profit and cash.
Questions
Did Johnson & Johnson raise or lower its guidance?
Johnson & Johnson (JNJ) raised some and lowered other parts of its guidance on Oct 13, 2026: Revenue $101.2B for FY2026; Revenue +7.4% for FY2026; EPS $10.95–$11.05 for FY2026.
What does Johnson & Johnson expect?
Subject to each covered entity’s submission of appropriate claims data, the Company will continue to offer the covered entity access to 340B pricing on the Company’s covered outpatient drugs up-front at the time of purchase. In October 2025, the Company announced its intention to separate its Orthopaedics business and expects the separation to be completed in mid-2027.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.